Oxymetholone ameliorates insulin sensitivity in maintenance hemodialysis patients: A randomized controlled trial

Clinical Nephrology

Volumn 71, Issue 4, 2009, Pages 413-422

  Aramwit, P ^a   Kobpipat, N ^a   Satirapoj, B ^b   Kopple, J D ^c   Supasyndh, O ^b  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b PHRAMONGKUTKLAO HOSPITAL   (Thailand)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Fat mass; Fat free mass; Hemodialysis; Insulin resistance; Oxymetholone

Indexed keywords

INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; OXYMETHOLONE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ACNE; ADULT; ANDROGEN THERAPY; ANTHROPOMETRIC PARAMETERS; ARTICLE; BARTHEL INDEX; BODY COMPOSITION; BODY FAT MASS; CELL STIMULATION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME BLOOD LEVEL; FAT FREE MASS; FEMALE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HEART MUSCLE ISCHEMIA; HEMODIALYSIS PATIENT; HEPATITIS; HOMEOSTASIS MODEL OF INSULIN RESISTANCE ASSESSMENT; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY FAILURE; LOW DRUG DOSE; LUTEINIZING HORMONE BLOOD LEVEL; MAINTENANCE THERAPY; MALE; MALIGNANT NEOPLASTIC DISEASE; METABOLIC PARAMETERS; MUSCLE CELL; MUSCLE FUNCTION; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SIDE EFFECT; SKELETAL MUSCLE; TESTOSTERONE BLOOD LEVEL;

EID: 66649131722     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP71413     Document Type: Article

References (42)

1. Berg A et al. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab. 2002; 13: 84-89.
2. Bhasin S et al. Testosterone replacement increases fat free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab. 1997; 82: 407-413.
3. Bhasin S et al. Proof of the effect of testosterone on skeletal muscle. J Endocrinol. 2001; 170: 27-38.
4. Bjorntorp P. "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis. 1990; 10: 493-496.
5. Brautbar N. Skeletal myopathy in uremia: abnormal energy metabolism. Kidney Int. 1983; 16 (Suppl): S81-86.
6. Brodsky I et al. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men-a clinical research center study. J Clin Endocrinol Metab. 1996; 81: 3469-3475.
7. Bross R et al. Anabolic interventions for aging-associated sarcopenia. J Clin Endocrinol Metab. 1999; 84: 3420-3430.
8. Chen X et al. Effects of testosterone on insulin receptor substrate-1 and glucose transporter 4 expression in cells sensitive to insulin. Zhonghua Yi Xue Za Zhi. 2006; 86: 1474-1477.
9. Demling R, and DeSanti L. Oxandrolone, an anabolic steroid, significantly increases the rate of weight gain in the recovery phase after major burns. J Trauma. 1997; 43: 47-51.
10. Diesel W et al. Morphologic features of the myopathy associated with chronic renal failure. Am J Kidney Dis. 1993; 22: 677-684.
11. Ferrando A et al. Testosterone administration to older menimproves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab. 2002; 282: E601-607.
12. Ferreira I et al. The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients. Chest. 1998; 114: 19-28.
13. Fouque D et al. Advances in anabolic interventions for malnourished dialysis patients. J Ren Nutr. 2003; 13: 161-165.
14. Handelsman D. Hypothalamic-pituitary gonadal dysfunction in renal failure, dialysis and renal transplantation. Endocr Rev. 1985; 6: 151-182.
15. Handelsman D, Dong Q. Hypothalamo-pituitary gonadal axis in chronic renal failure. Endocrinol Metab Clin North Am. 1993; 22: 145-161.
16. Herbst K et al. Effects of transdermal testosterone administration on insulin sensitivity, fat mass and distribution, and markers of inflammation and thrombolysis in human immunodeficiency virus-infected women with mild to moderate weight loss. Fertil Steril. 2006; 85: 1794-1802.
17. Holmang A, Bjorntorp P. The effects of testosterone on insulin sensitivity in male rats. Acta Physiol Scand. 1992; 146: 505-510.
18. Ito C et al. Correlation among fasting plasma glucose, two-hour plasma glucose levels in OGTT and HbA1c. Diabetes Res Clin Pract. 2000; 50: 225-230.
19. Johansen K et al. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA. 1999; 281: 1275-1281.
20. Kapoor D et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006; 154: 899-906.
21. Kapoor D et al. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2007; 156: 595-602.
22. Katznelson L et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab. 1996; 81: 4358-4365.
23. Kobayashi S et al. Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis. 2005; 45: 275-280.
24. Konukoglu D et al. Plasma homocysteine levels in obese and non-obese subjects with or without hypertension; its relationship with oxidative stress and copper. Clin Biochem. 2003; 36: 405-408.
25. Kopple J. Effect of nutrition on morbidity and mortality in maintenance dialysis patients. Am J Kidney Dis. 1994; 24: 1002-1009.
26. Lansang M et al. Correlation between the glucose clamp technique and the homeostasis model assessment in hypertension. Am J Hypertens. 2001; 14: 51-53.
27. Ma K et al. Cardiovascular risk factors in chronic renal failure and hemodialysis populations. Am J Kidney Dis. 1992; 19: 505-513.
28. Malkin C et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004; 89: 3313-3318.
29. Marin P et al. Androgen treatment of middle-aged, obese men: effects on metabolism, muscle and adipose tissues. Eur J Med. 1992; 1: 329-336.
30. Marin P et al. Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. J Clin Endocrinol Metab. 1995; 80: 239-243.
31. Matthews D et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28: 412-419.
32. Mauras N et al. Ovarian hyperandrogenism is associated with insulin resistance to both peripheral carbohydrate and whole-body protein metabolism in postpubertal young females: a metabolic study. J Clin Endocrinol Metab. 1998; 83: 1900-1905.
33. Pavlatos AM et al. Review of oxymetholone: a 17 alpha-alkylated anabolic-androgenic steroid. Clin Ther. 2001; 23: 789-801; discussion 771.
34. Rigalleau V, and Gin H. Carbohydrate metabolism in uraemia. Curr Opin Clin Nutr Metab Care. 2005; 8: 463-469.
35. Rudich A et al. Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. Diabetes. 1998; 47: 1562-1569.
36. Satirapoj B et al. The correlation of insulin resistance and renal function in non diabetic chronic kidney disease patients. J Med Assoc Thai. 2005; 88: S97-104.
37. Sheffield-Moore M et al. Short-term oxandrolone administration stimulates net muscle protein synthesis in young men. J Clin Endocrinol Metab. 1999; 84: 2705-2711.
38. Shinohara K et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol. 2002; 13: 1894-1900.
39. Singh R et al. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology. 2003; 144: 5081-5088.
40. Stout R. Diabetes and atherosclerosis-the role of insulin. Diabetologia. 1979; 16: 141-150.
41. Tsao T et al. ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol. 2002; 440: 213-221.
42. Urban R et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol. 1995; 269: E820-826.